K36 Therapeutics raises $70M in Series B to fund multiple myeloma research
K36 Therapeutics raised $70 million to help fund an ongoing clinical trial for its lead and only candidate, an oral multiple myeloma treatment.
The Cambridge, MA-based biotech on Wednesday revealed the new cash influx. The Series B was led by VC Nextech Invest and included Bristol Myers Squibb and all previous investors, such as Eight Roads Ventures, Atlas Venture and F-Prime Capital.
The biotech broke out of stealth back in December 2021, with $30 million from a Series A that closed earlier that year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.